| Filed On | Filing |
|---|---|
| 03 Nov 2026 |
8-K: Results of Operations and Financial Condition
SAN DIEGO – November 3, 2026 – Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases w... |
| 14 Sep 2026 |
8-K: Other Events
–Phase 2 MOONLIGHT-1 trial did not meet its primary efficacy endpoint |
| 30 Jul 2026 |
8-K: Results of Operations and Financial Condition
SAN DIEGO – July 30, 2026 – Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with... |
| 13 Jul 2026 |
8-K: Regulation FD Disclosure
Disclaimer 2 This presentation by Contineum Therapeutics, Inc. (“Contineum”, “We” or “Our) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statemen... |
| 26 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 26, 2026, Contineum Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 27, 2026, the record date for the Annual Meeting, there were 32,723,877 shares of Class A com... |
| 05 May 2026 |
8-K: Results of Operations and Financial Condition
SAN DIEGO – May 5, 2026 – Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunolo... |
| 30 Apr 2026 |
8-K: Regulation FD Disclosure; Other Events
–The trial achieved its primary endpoint demonstrating favorable safety and tolerability |
| 05 Mar 2026 |
8-K: Results of Operations and Financial Condition; Other Events
- Patient dosing initiated in PROPEL-IPF, a global Phase 2 trial evaluating PIPE-791 for the treatment of patients with idiopathic pulmonary fibrosis (IPF) |
| 26 Jan 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On January 23, 2026, the Board of Directors (the “Board”) of Contineum Therapeutics, Inc. (the “Company”) approved the Continuem Therapeutics, Inc. 2026 Employment Inducement Equity Incentive Plan (the “2026 Inducement Plan”). The terms ... |
| 15 Dec 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
As representatives (the “Representatives”) of the several Underwriters |
| 11 Dec 2025 |
8-K: Other Events
On December 8, 2025, the Company submitted the details of its global Phase 2 clinical trial of PIPE-791 to treat patients with idiopathic pulmonary fibrosis (IPF) to the ClinicalTrials.gov Protocol Registration and Results System (PRS). ... |
| 20 Nov 2025 |
8-K: Other Events
CONTINEUM THERAPEUTICS REPORTS TOPLINE DATA FROM ITS PHASE 2 PIPE-307 VISTA TRIAL FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) |
| 30 Oct 2025 |
8-K: Results of Operations and Financial Condition
- Topline data from the PIPE-307 Phase 2 VISTA trial for the treatment of relapsing-remitting multiple sclerosis (RRMS) is anticipated in the fourth quarter of 2025 |
| 18 Sep 2025 |
8-K: Regulation FD Disclosure; Other Events
- PIPE-791 achieved high LPA1 brain receptor occupancy (RO) in healthy volunteers and progressive multiple sclerosis (PrMS) patients |
| 05 Aug 2025 |
8-K: Results of Operations and Financial Condition
- Topline data from the PIPE-307 Phase 2 VISTA trial for the treatment of relapsing-remitting multiple sclerosis (RRMS) is anticipated in the fourth quarter of 2025 |
| 26 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 26, 2025, Contineum Therapeutics, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 28, 2025, the record date for the Annual Meeting, there were 19,142,377 shares of Class A com... |
| 14 May 2025 |
8-K: Results of Operations and Financial Condition; Other Events
- Topline data from PIPE-791 Phase 1b positron emission tomography (PET) trial expected in the second quarter of 2025 |
| 28 Apr 2025 |
8-K: Other Events
SAN DIEGO – April 28, 2025 – Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immun... |
| 17 Mar 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On March 14, 2025, the board of directors (the “Board”) of Contineum Therapeutics, Inc. (the “Company”) appointed Diego Miralles, M.D. as a member of its Board, effective March 14, 2025. Dr. Miralles will serve as a Class II director wit... |
| 06 Mar 2025 |
8-K: Results of Operations and Financial Condition
- Topline data from PIPE-791 Phase 1b positron emission tomography (PET) trial expected in the second quarter of 2025 |
Loading...